Biogen and Eisai to seek regulatory approval for Alzheimer's medicine

Following a successful late-stage clinical trial in which cognitive decline caused by Alzheimer’s was delayed by 27%, the two companies are ready to head down the market authorization road.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Pharmaceutical companies Biogen and Eisai are ready to seek regulatory approval for a new drug targeting Alzheimer’s treatment after a phase III trial provided favorable results, the Financial Times writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs